SCHEMBL2793307

SCHEMBL2793307

NC(CC(=O)NCCc1ccc(Cl)cc1)c1ccc(C(=O)Nc2ccncc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NT5E P21589 1/20 0.55
KMT2A Q03164 1/20 0.55
KDM4E B2RXH2 2/20 0.51
NAMPT P43490 3/20 0.50
ROCK2 O75116 2/20 0.50
ROCK1 Q13464 2/20 0.50
MAPK1 P28482 1/20 0.49
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
MAPT P10636 2/20 0.46
CYP1A2 P05177 1/20 0.46
GAA P10253 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
GFER P55789 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
MCHR1 Q99705 1/20 0.45
CNR1 P21554 2/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2790925 0.90 RAB9A (0.56) KMT2AKDM4ENAMPTROCK2ROCK1
SCHEMBL2793989 0.90 NAMPT (0.55) KMT2AKDM4ENAMPTROCK2ROCK1
SCHEMBL2790576 0.90 RAB9A (0.54) KMT2AKDM4ENAMPTROCK2ROCK1
SCHEMBL2794919 0.89 HIF1A (0.52) KDM4ENAMPTROCK2ROCK1L3MBTL1
SCHEMBL2792873 0.88 NAMPT (0.49) NT5EKMT2ANAMPTROCK2ROCK1
SCHEMBL2792960 0.88 NAMPT (0.53) KMT2ANAMPTROCK2ROCK1NPC1
SCHEMBL2792181 0.88 ROCK2 (0.51) KMT2ANAMPTROCK2ROCK1NPC1
SCHEMBL2790563 0.86 KMT2A (0.48) NT5EKMT2AKDM4ENAMPTROCK2
SCHEMBL2790105 0.85 HDAC1 (0.51) KMT2ANAMPTROCK2ROCK1NPC1
SCHEMBL2790570 0.84 ROCK2 (0.48) NT5EKMT2AKDM4ENAMPTROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100168102-A9 Amide Derivatives as Kinase Inhibitors DEVGEN NV (BE) 2010-07-01 US disclosed
US-20090118283-A1 Amide Derivatives as Kinase Inhibitors DEVGEN NV (BE) 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168102-A9 Amide Derivatives as Kinase Inhibitors MAP3K1, CDK1, CDK2 NT5E 4666/4885KMT2A 1918/4885KDM4E 4352/4885
US-20090118283-A1 Amide Derivatives as Kinase Inhibitors MAP3K1, CDK1, CDK2 NT5E 4666/4885KMT2A 1918/4885KDM4E 4352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.